Summary.-Six anilinoacridine derivatives have been tested for the ability to act as radiosensitizers. Two gave good sensitization at concentrations of 100 pM or less.
Both of these are known to possess significant activity against experimental tumours, and one (m-AMSA) is in Phase II clinical trial as a chemotherapeutic drug. Anilinoacridines may have potential as drugs with both a chemotherapeutic and radiosensitizing role. In spite of their structural similarity, the 2 derivatives which sensitize do so by different mechanisms. Compound VI behaves like a typical hypoxic cell sensitizer but Compound I (m-AMSA) interferes with the accumulation of sublethal damage in either the presence or absence of 02. The latter also displays a postirradiation sensitizing effect. Differences in mechanism may be related to the relative DNA-binding abilities and electronic differences between the 2 drugs.
RESEARCH aimed at improving the radiotherapeutic management of cancer patients can be considered in two broad categories. Firstly, evidence is sought of a therapeutic gain from the combination of radiotherapy and alternate treatment modes, particularly chemotherapy (IAEA, 1977; Leenhouts & Chadwick, 1978) . Secondly, there is research attempting to increase the intrinsic tumour response to radiation, which includes the use of chemicals to sensitize hypoxic cells selectively. One group of hypoxic cell sensitizers, the nitro-imidazoles, has received detailed experimental study, and recent cautious clinical application (Fowler et al., 1976) . The finding that these nitroimidazoles (or, possibly, their metabolites) are preferentially toxic to hypoxic cells has provided a potential link between radiosensitizers and chemotherapy (Hall & Roizin-Towle, 1975; Mohindra & Rauth, 1976; Stratford & Adams, 1977) . Cells subjected to sufficiently severe hypoxia stop progressing through the cell cycle, an effect which can also be induced in tumours by other conditions such as the deprivation of certain nutrients, cellular over-crowding and non-optimal temperature and pH. Most available anti-tumour drugs are more effective against cells in cycle than those out of cycle, and the non-cycling, clonogenic cells of a tumour may present a major problem in current therapy. Nitroimidazoles may prove to be useful against these non-cycling cells, although Brown (1977) has pointed out that hypoxia rather than the non-cycling of the cells may be responsible for the preferential toxicity.
There has been recent interest in a series of 9-anilino-acridines which are tumour-inhibitory (Denny et al., 1978, and references therein) . One member of the series, m-AMSA (NSC249992) is at present in Phase II clinical trial under the auspices of the American National Cancer Institute. This novel aminoacridine derivative has comparable degrees of cytotoxicity towards both cycling and non-cycling Chinese hamster ovary cells in culture (Tobey et al., 1978 known to possess radiosensitizing ability in a variety of experimental systems, including some using mammalian cells (Arlett, 1970; Fuks & Smith, 1971; Bleehan et al., 1974) . Both quinacrine and acriflavine intercalate between the base pairs in twin-helical DNA where, it is suggested, they inhibit the function of "'repair enzymes". Actinomycin D, which possesses a planar tricyclic ring system comparable to that of the aminoacridines, is also an intercalating agent and an effective sensitizer of mammalian cells in vitro (Elkind & Whitmore, 1967) . This sensitizing ability may be the reason for the enhanced tissue response in radiotherapy patients who have received the drug (Piro et al., 1975) .
Studies on representative tumour-active 9-anilinoacridines (including m-AMSA) have shown that these compounds are also DNA-intercalating agents (Waring, 1976 ) and clearly such agents should be examined for radiosensitizing ability. After encouraging preliminary results with m-AMSA in a bacterial system, a group of 9-anilinoacridines was examined with the ultimate aim of developing quantitative molecular structure-activity relationships (QSAR) for the radiosensitizing abilities of members of this class of compound.
Development of QSAR for the sensitizing properties of these compounds would aid in the selection of further analogues for more extensive testing. Work in progress with some 9-anilino-acridines has demonstrated the existence of such QSAR for both in vivo anti-tumour activity and mutagenic potential. This paper reports the sensitizing abilities of the limited number of compounds tested so far and an unexpected difference in the mechanism of action of the 2 most effective sensitizers.
MATERIALS AND METHODS
Six 9-anilinoacridine derivatives (I-VI) were selected, and prepared as described elsewhere (Cain et al., 1975; Atwell et al., 1977; Denny et al., 1978) . These include the clinical-trial candidate m-AMSA (I) and, as many excellent radiosensitizers contain a nitro group, the tumour-inhibitory 3-nitro analogue II. Because of the relative insolubility of II, a more soluble tumourinhibitory 3-nitro derivative (III) was examined, as was an inactive compound (IV) which has a nitro group in an alternative position. Two other derivatives with different electron-withdrawing groups in the same position as the nitro group of (IV), the inactive sulphonamide (V) and the tumour-inhibitory carboxylic acid derivative (VI) were also included. Solutions of the salts of these com-
pounds were prepared in distilled water just before use, and diluted into the bacterial suspension to provide the appropriate concentration. It should be noted that the solubility of the drugs was reduced 4-to 10-fold in the phosphate-buffered suspensions (66mM phosphate salts, pH 7-0 + 0-1). Drug toxicity, and the ability of the drug to sensitize when present at the time of irradiation, were evaluated with E. coli B/r cells grown to late log phase in tryptone-glucoseyeast (TGY) medium at 37°C. The cells were filtered, washed, and suspeinded in buffer at a density of about 107 cells/ml. After exposure to the drug, to radiation, or to the combination of drug plus irradiation, cell survival was estimated by dilution of the cells into buffer and plating out on TGY agar followed by overnight incubation at 37°C. Irradiations were carried out at room temperature using a Gammacell-220 60Co source and a dose rate of , 10 krad/min. Moist air or N2 (less than 12 parts in 106 02 as determined in the effluent gas by a Hersch cell) was bubbled through the suspensions as required. For experiments in which the postirradiation effect of the drug was tested, the growth medium contained a minimal salts medium (4-4 g Na2HPO4, 2-7 g KH2PO4, 1-0 g (NH4)2SO4, 0-14 mg FeSO4, 100 mg MgSO4.7H20, and 5 mg Ca(NO3)2 per litre of distilled water). Late log-phase cells were filtered, washed and suspended in this minimal-salts medium. The suspension was then irradiated for 2-5 or 4 min (25 or 40 krad) and then supplemented with glucose (0-2%), casamino acids (0-5 g/l) and thiamine (1 mg/l) within half a minute. Drug was also added within this period if required, and the suspension was incubated at 40C or 37°C. Aliquots were taken at intervals and diluted and plated out as above.
RESULTS
All the anilinoacridines tested were degraded by radiation. This degradation, which could be conveniently monitored by the decrease in optical absorbance in the spectral region 400-450 nm, occurred whether in the presence or absence of bacteria, and was somewhat greater in air than in N2. Thus, 50% loss of the chromophore was found after 20 krad (in air) and 30 krad (in N2) for Compound VI. With Compound I, the equivalent doses were 60 and 100 krad. This degradation is not surprising, since it is known that the 9-anilinoacridines suffer chemical cleavage in biological media which contain nucleophilic species (Cain et al., 1976; Wilson et al., 1977) . The products of radiationinduced degradation were less toxic than the parent compounds in each case. At the radiation doses used in our experiments, some degradation would be expected, and all the concentrations quoted should be regarded as initial values.
Because of extreme insolubility, IV could not be tested at concentrations above 1 ztM. drug. Thus, toxic effects during the 30min exposure to the drug before irradiation did not produce a population of drugresistant cells with altered radiation susceptibility.
The effect of addition of 100 tuM of I immediately after 25 krad irradiation, under conditions which promote growth in cell numbers (supplemented minimal-salts medium), is shown in Fig. 2 in air (Fig. 3) . With this compound, sensitization of hypoxic cells occurred via an increase in the slope of the survival curve rather than reduction of the shoulder. Again, a standard protocol was used in all experiments, the freshly suspended cells in buffer being exposed to the drug for 30 min before irradiation. In spite of this, considerable variability was seen in the hypoxic enhancement ratio (the ratio of the slopes of the survival curves with and without drug) in experiments which were carried out close to the solubility limit of 50 juM, as shown in Fig. 4 . The reason for this is not clear, but temperature and light sensitivity of the drug do not appear responsible. Fig. 4 also shows that some sensitization was seen at concentrations as low as 15 juM. Compound VI was tested for post-irradiation effects, but none were observed, even at the upper concentration limit of 50 VM (Fig. 5) .
Compound V At the solubility limit for this compound (40-50 ,uM) (Shoemaker et al., 1978) as there is for the selective uptake of the aminoacridine quinacrine (Ackerman et at., 1965; Anghileri, 1966 A most striking aspect of this preliminary work is the fact that the two most effective compounds, I and VI, sensitize the bacterial cells to radiation in different ways. The carboxylic-acid derivative VI appears to act as a typical hypoxic-cell sensitizer. It increases the lethal effects of radiation to cells in the absence of 02, increasing the survival-curve slope, but has no effect in the presence of 02. The compound does not show any postirradiation effects. In contrast, Compound I acts by eliminating the shoulder observed on the survival curve at low doses, which implies a removal of the ability to accumulate sub-lethal damage. This effect occurs both in the presence and absence of 02. Compound I is also an effective postirradiation sensitizer, an ability similar to that displayed by quinacrine (Fuks & Smith, 1971) . For quinacrine, there is evidence that it interferes with the repair of damaged DNA, probably via drug intercalation into the DNA base pairs. The maximum post-irradiation enhancement of radiation damage found with quinacrine was far greater than that seen in this study with I, but these maximum effects were observed at toxic quinacrine levels. When the two compounds are compared at non-toxic levels (100,UM and below) quinacrine appears to be about 3-to 5-fold more effective than I. If drug intercalation into DNA is indeed involved in post-irradiation sensitization, these differences are not surprising, because quinacrine binds much more strongly to DNA than does Compound I . The post-irradiation enhancement shown by I clearly involves slow processes (see Fig. 2 ), and is inhibited at 4°C. This implies the type ofrepair operationally defined as Type III by Town et al. (1973) .
The simplest explanation consistent with the observations is that I interferes with repair enzymes which otherwise would eliminate potentially lethal cell damage after irradiation. As a result of this interference, potentially lethal damage can be expressed when the cells are stimulated to divide. No data have been reported on sensitization by quinacrine when it is present at the time of irradiation, so that no comparison with the observations of Fig. 1 can be made. However, if it is accepted that the accumulation of sublethal damage is also under the control of a repair enzyme system, then the results are reasonable.
The reasons for the different sensitizing effects shown by these two similar compounds (I and VI) is not clear. It is known that Compound I binds much more strongly to calf thymus DNA than does the carboxylic acid VI (Baguley, personal communication), and there are also substantial differences in charge distribution between the two derivatives. The pKa of the acid group of VI is [4] [5] [6] (Atwell, personal communication) , and at the pH of the buffer used (7 0 + 0 1) it will exist almost entirely as the anion. The electronic nature of groups in the anilino ring of the 9-anilinoacridines has a marked effect on their anti-tumour activity (Atwell et al., 1972) ; the same appears to be true for their radiosensitizing properties.
